SEC Tracker
Get the app

Tango Therapeutics TNGX

Tango Therapeutics reports positive trial results

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. 82% objective response rate in PDAC patients
  2. 88% 9-month PFS rate in PDAC patients
  3. Vopimetostat plus daraxonrasib well-tolerated
  4. FDA to initiate global trial in 2027

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Tango Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
  2. Iovance Biotherapeutics IOVA public float $535M, Jun 30, 2025
  3. Opko Health OPK public float $540M, Dec 31, 2025
  4. Savara SVRA public float $544M, Jun 30, 2025
  5. Xencor XNCR public float $556M, Jun 30, 2025